INVO Fertility, Inc.

Listed Company

IVFCIK 0001417926NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusNevadaFY ends Dec 31

Period

FY 2025

Revenue

$6.84M

Net Income

$-23.32M

Total Assets

$20.22M

Equity

$7.22M

Shares Out

1.79M

Op. Cash Flow

$-7.01M

Business

INVO Fertility, Inc. is a healthcare services company focused on the fertility marketplace that builds, acquires, and operates fertility clinics to expand access to assisted reproductive technology (ART). It offers clinical fertility services including intravaginal culture (IVC) using the INVOcell® medical device, in vitro fertilization (IVF), intrauterine insemination (IUI) and related clinic-based services, and distributes INVOcell to third‑party clinics. Its key business segments include Fertility Clinics, the INVOcell Device, and a Therapeutics segment (NAYA Therapeutics). The company primarily operates in the United States through wholly owned clinics, joint ventures, direct sales to clinics, and partnerships while remaining open to selective international distribution relationships.

Summary from filing dated 2025-04-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31
Revenue:	—	—
Revenue	7	7
Operating expenses:	—	—
Cost of services	4	4
Cost of Revenue	30,571	12,201
Selling, General and Administrative Expense	8	8
Research and Development Expense	—	4,880
Amortization of Intangibles	1	—
Loss on disposal of fixed assets	—	−511,663
Depreciation Expense	677,364	919,603
Total operating expenses	14	13
Loss from operations	−7	−7
Other income (expense):	—	—
Income from Equity Method Investments	31,294	9,045
Non-Operating Income (Expense)	5	—
Net Cash from Operating Activities	—	94,551
Extinguishment loss	−2	−40,491
Loss on issuance of warrants	943,862	—
Gain on settlement of liability (Note 18)	929,500	—
Interest expense	1	1
Total other income (expenses)	2	−972,038
Net loss before income taxes	−5	−8
Income Tax Expense	−150,371	140,202
Net loss from continuing operations	−5	−8
Extraordinary Items	−2	—
Extraordinary Items	−16	−2
Net loss	−23	−9
Preferred stock dividends and deemed dividends	2	250,635
Net loss attributable to common shareholders	−25	−10
Net loss from continuing operations per common share:	—	—
Basic	−45.57	−3,079
Diluted	−45.57	−3,079
Net loss from discontinued operations per common share:	—	—
Basic	−153.63	−604.21
Diluted	−153.63	−604.21
Earnings Per Share	—	—
Basic	−214.64	−3,783
Diluted	−214.64	−3,783
Shares Outstanding	—	—
Basic	117,083	2,514
Diluted	117,083	2,514

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31
ASSETS	—	—
Current assets	—	—
Cash and Cash Equivalents	2	619,520
Accounts Receivable	217,263	113,108
Inventory	225,253	219,764
Other Non-Operating Current Assets	241,145	180,853
Assets Held for Sale	—	123,313
Total current assets	3	1
Property, Plant and Equipment	386,165	466,684
Operating Lease Right-of-Use Asset	1	1
Intangible Assets	1	3
Goodwill	6	6
Long-Term Investments	2	—
Notes Receivable, Non-Current	6	1
Noncurrent assets held for disposition	—	32
Total assets	20	46
LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY	—	—
Current liabilities	—	—
Accounts Payable	2	3
Accrued Compensation and Benefits	285,946	713,483
Short-Term Debt	1	6
Deferred Revenue, Current	721,897	602,359
Operating Lease Liability, Current	208,987	181,132
Other Non-Operating Current Liabilities	4	3
Other Non-Operating Current Liabilities	2	—
Other Non-Operating Current Liabilities	—	410,000
Other Non-Operating Current Liabilities	—	4
Total current liabilities	10	18
Operating Lease Liability, Non-Current	1	1
Liability for excess losses of equity method investee	448,474	479,768
Long-Term Debt	744,725	1
Deferred Tax Liabilities, Current	—	163,115
Other Non-Operating Non-Current Liabilities	300,000	5
Total liabilities	13	26
Temporary Equity	—	7
Stockholders’ equity	—	—
Preferred Stock	2	30
Total Stockholders' Equity	239	37
Additional Paid-In Capital	96	50
Retained Earnings	−91	−67
Total stockholders’ equity	7	13
Total liabilities, mezzanine, and stockholders’ equity	20	46

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31
Cash flows from operating activities:	—	—
Net loss	−23	−9
Adjustments to reconcile net loss to net cash used in operating activities:	—	—
Net Cash from Operating Activities	1	1
Total Costs and Expenses	—	153
Net Cash from Operating Activities	178,729	342,728
Non-cash compensation for services	135,000	180,000
Interest Expense	1	622,283
Asset Impairment Charges	16	—
Reserve on other assets	—	498,592
(Gain) Loss from equity method investment	31,294	9,045
Loss from debt extinguishment	−2	−40,491
Loss on disposal of fixed assets	—	−511,663
Gain on lease termination	—	94,551
Loss on disposition	−2	—
Fair value of warrants	943,862	—
Gain on changes in fair value	5	—
Gain on settlement	929,500	—
Depreciation and amortization	677,364	919,603
Changes in assets and liabilities:	—	—
Accounts receivable	104,155	−27,442
Inventory	5,489	−44,743
Prepaid expenses and other current assets	120,472	163,761
Equity investments	—	−4,534
Change in Accounts Payable	−1	1
Accrued compensation	−153,265	274,665
Deferred revenue	119,538	193,590
Other current liabilities	−60,000	—
Net Cash from Operating Activities	10,721	−35,904
Net Cash from Operating Activities	119,095	166,772
Deferred tax liabilities	−163,115	163,115
Net cash used in operating activities	−7	−3
Cash used in investing activities:	—	—
Payments to acquire property, plant, and equipment	43,412	183,703
Proceeds from Sale of PP&E	—	75,590
Net Cash from Investing Activities	—	472,008
Divesture of NTI	6,569	—
Payment for acquisitions	3	—
Net cash used in investing activities	−3	363,895
Cash from financing activities:	—	—
Net Cash from Financing Activities	—	1
Stock Repurchases (Issuances)	12	165,131
Proceeds from the sale of preferred stock	3	2
Net Cash from Financing Activities	1	900,611
Preferred stock redemption	4	—
Principal payments on notes payable	1	934,419
Net cash provided by financing activities	11	3
Increase in cash and cash equivalents	1	508,972
Cash and cash equivalents at end of period	—	—
Cash and cash equivalents at end of period	—	—
Supplemental disclosure of cash flow information:	—	—
Interest Expense	644,158	214,742
Income Tax Expense	—	—
Noncash activities:	—	—
Fair value of preferred stock issued for acquisition	—	25
Common stock and preferred stock issued upon conversion notes payable and accrued interest	5	387,033
Dividends on preferred stock	718,616	—
Deemed dividend	1	250,635
Net Cash from Operating Activities	167,863	188,755
C-2 to common stock exchange	14	—
Preferred stock redemption adjustment	521,922	—
Preferred stock exchange	1	—
Common stock issued for accounts payable	23,460	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro